Get the Stockscreener App
1.56
4.70%
0.07
After Hours:
1.57
0.01
+0.64%
Inmune Bio Inc stock is traded at $1.56, with a volume of 315.05K.
It is up +4.70% in the last 24 hours and down -18.32% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.49
Open:
$1.47
24h Volume:
315.05K
Relative Volume:
0.77
Market Cap:
$41.47M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-0.9341
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-2.50%
1M Performance:
-18.32%
6M Performance:
-38.34%
1Y Performance:
-71.16%
1-Day Range:
$1.47
$1.58
1-Week Range:
$1.47
$1.63
52-Week Range:
$1.38
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.56 | 39.61M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Can INmune Bio Inc. stock withstand economic slowdown2026 world cup usa national team round of 32 defensive leaders low block defense expert forecast expert opinion - Улправда
INmune Bio Inc Stock Analysis and ForecastTechnology Stock Trends & Exceptional Capital Growth - earlytimes.in
How INmune Bio Inc. stock performs in high volatility marketsEnergy Sector Updates & Small Investment Capital Tips - bollywoodhelpline.com
Inmune Bio Amends April 2024 Investor Warrants - TipRanks
INMB (INmune Bio) EV-to-OCF : -0.76 (As of Dec. 22, 2025) - GuruFocus
INMB (INmune Bio) EV-to-FCF : -0.75 (As of Dec. 22, 2025) - GuruFocus
Aug Wrap: How interest rate cuts could boost INmune Bio Inc stockQuarterly Earnings Summary & Real-Time Buy Signal Notifications - moha.gov.vn
Winners Losers: What is the fair value of INmune Bio Inc stock nowChart Signals & Accurate Trade Setup Notifications - moha.gov.vn
Gains Report: Is INmune Bio Inc stock a top pick in earnings seasonQuarterly Portfolio Review & Weekly Watchlist of Top Performers - moha.gov.vn
Why analysts upgrade INmune Bio Inc. stockMarket Performance Recap & Expert Curated Trade Ideas - Улправда
INmune Bio Establishes $65 Million At-The-Market Offering - The Globe and Mail
Is INmune Bio Inc. stock vulnerable to regulatory risksMarket Weekly Review & AI Forecasted Stock Moves - Улправда
Will INmune Bio Inc. stock attract more institutional investorsLayoff News & Smart Money Movement Alerts - Улправда
Aug Highlights: Is INmune Bio Inc. stock attractive for long term wealth buildingWeekly Trading Summary & Verified Technical Trade Signals - Улправда
INMune Bio establishes $65 million at-the-market offering - MSN
Is INmune Bio Inc. stock a good choice for value investorsRecession Risk & Real-Time Buy Zone Alerts - Улправда
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
Is INmune Bio Inc. stock resilient to inflation2025 Fundamental Recap & Community Verified Trade Alerts - DonanımHaber
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
Is INmune Bio Inc. stock a top pick in earnings season2025 Volatility Report & Consistent Income Trade Ideas - DonanımHaber
INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN
INmune Bio Earnings Notes - Trefis
INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen - MarketBeat
Aug Closing: Is INmune Bio Inc stock resilient to inflationTrade Risk Report & Expert Verified Movement Alerts - moha.gov.vn
Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB - MarketBeat
Inmune Bio to Host Q3 Results Conference Call - MSN
Inmune Bio Reports Q3 2025 Financial Results - MSN
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
Can INmune Bio Stock Hold Up When Markets Turn? - Trefis
Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth? - Sahm
Would You Still Hold INmune Bio Stock If It Fell 30%? - Trefis
Inmune Bio Unveils Promising Alzheimer’s Trial Data - MSN
Insider Sell: Why INmune Bio Inc stock could see breakout soonJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - moha.gov.vn
Retail Trends: Can INmune Bio Inc stock beat analyst upgradesMarket Activity Report & Verified Chart Pattern Signals - BỘ NỘI VỤ
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as Inmune Bio's CORDStrom?? Platform - marketscreener.com
INMB: INmune Bio Highlights Future Potential of MSC Therapies - GuruFocus
INmune Bio, Inc. Announces Publication on Future Applications of Mesenchymal Stromal Cell Therapies - Quiver Quantitative
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform - The Manila Times
Inmune Bio Updates Executive Employment Agreements - TipRanks
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Could INmune Bio Unlock Value With Upcoming Regulatory Catalysts And Clinical Readouts? - RTTNews
Why INmune Bio Inc. stock could see breakout soonWeekly Loss Report & Daily Momentum Trading Reports - Newser
Can INmune Bio Inc. stock beat analyst upgradesStock Surge & Free Technical Confirmation Trade Alerts - Newser
Can INmune Bio Stock Recover If Markets Fall? - Trefis
Can INmune Bio Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - Newser
INmune Bio reports promising Alzheimer’s drug data at CTAD conference By Investing.com - Investing.com Canada
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):